FBXO30 and benign prostatic hyperplasia: Bjerre et al. [12] investigated the diagnostic and prognostic potential of a three-gene methylation ctDNA signature consisting of DOCK2, HAPLN3, and FBXO30. This signature was able to differentiate de novo, primarily high-volume metastatic PCa; however, was not able to differentiate between healthy controls, benign prostatic hyperplasia and localized PCa.